Large phase III trials showed that afatinib performed well as first-line treatment in tumours bearing exon 19 deleted EGFR [44], but was unexpectedly ineffective on L858R mutant tumours or on gefitinib or erlotinib-pretreated tumours with a predominant T790M mutation. Here, EGFR is linked to neoplasm.